Navigation Links
DARA BioSciences, Inc. Announces Appointment of New Director to Board
Date:2/27/2008

RALEIGH, N.C., Feb. 27 /PRNewswire-FirstCall/ -- DARA BioSciences(TM) (Nasdaq: DARA) announced today the appointment of Haywood D. Cochrane, Jr. to the Board of Directors. Mr. Cochrane was appointed to fill a Board vacancy and will serve on the Company's Audit and Compensation Committees. The appointment was effective February 21, 2008.

In making the announcement DARA's Board Chairman, Richard Franco, Sr., commented, "We are pleased that Haywood has joined us as a Director. His vast knowledge and successful experience in the healthcare industry will further strengthen DARA's already skilled Board."

Mr. Cochrane is currently Vice Chairman and a Director of I-trax, Inc. (Amex: DMX), a publicly traded, total population health management and productivity company. Mr. Cochrane has previously served as a Director of seven other publicly-traded companies.

About DARA BioSciences, Inc.

DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly or through investment in established companies. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including type 2 diabetes, dyslipidemia and dermatological disorders. DARA has licensed promising drug development candidates from Kirin Pharmaceuticals of Japan, Bayer Pharmaceuticals Corporation, Massachusetts General Hospital and Nuada LLC.

For more information please contact the Company at 919-872-5578 or visit our web site at http://www.darabio.com.

All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934 as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected. Those factors include risks and uncertainties relating to the company's ability to develop and bring new products to market as anticipated, the current regulatory environment in which the company develops and sells its products, the market acceptance of those products, dependence on partner, successful performance under collaborative and other commercial agreements, competition, the strength of DARA's intellectual property, the intellectual property of others and other risk factors identified in the documents DARA has filed, or will file, with the Securities and Exchange Commission. Copies of DARA's filings with the SEC may be obtained from the SEC Internet site at http://www.sec.gov. DARA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DARA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.


'/>"/>
SOURCE DARA BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
2. Pressure BioSciences, Inc. Provides Corporate Update
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320
5. Pressure BioSciences, Inc. Issued First Patent in Canada
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
8. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
9. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
10. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
11. ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Today, the South Davis ... Advanced Biological Nutrient Recovery (ABNR™) technology at its 4,000,000 gallon per day South ... to sustainably meet current and future nutrient discharge regulations. The ABNR platform, which ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... FileSend, a cloud-based file transfer solution that makes it easy for organizations to ... having to worry about cumbersome FTP software or email file size limitations. ...
(Date:5/23/2017)... Washington, USA (PRWEB) , ... May 22, 2017 ... ... SPIE Optics and Photonics 2017 in San Diego, California, this August will ... reality, solar fuels, and autonomous vehicles. , SPIE Optics and Photonics, the largest ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge Semantics , the leading provider of ... Bio-IT World Conference and Expo in Boston May 23-25 with a featured speaker ... Anzo Smart Data Lake is also a finalist for the Best of Show award. ...
Breaking Biology Technology:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
(Date:3/22/2017)... March 21, 2017   Neurotechnology , a ... technologies, today announced the release of the ... provides improved facial recognition using up to 10 ... single computer. The new version uses deep neural-network-based ... and it utilizes a Graphing Processing Unit (GPU) ...
(Date:3/20/2017)... Germany , March 20, 2017 At this ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG ... is this year,s CeBIT partner country. At the largest German ... biometrics in use: fingerprint, face and iris recognition as well as DERMALOG´s ... ...
Breaking Biology News(10 mins):